Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dan'ge Fentong is a Traditional Chinese Medicine (TCM) formulation developed by the Sichuan Academy of Chinese Medicine Sciences, specifically designed for the treatment of type 2 diabetes mellitus and diabetic peripheral neuropathy (DPN). The preparation is primarily composed of extracts from *Salvia miltiorrhiza* (Danshen) and *Pueraria lobata* (Gegen), with key active constituents including salvianolic acids and puerarin. Its mechanism of action is multi-targeted, focusing on improving blood microcirculation, reducing oxidative stress, and inhibiting the release of pro-inflammatory cytokines such as TNF-alpha and IL-6. By addressing these pathways, Dan'ge Fentong aims to protect peripheral nerve fibers from damage caused by chronic hyperglycemia and improve nerve conduction velocity in diabetic patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dan'ge Fentong.